Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs, colchicine, corticosteroids, and anti-IL-1 agents. Long-term urate-lowering drugs (ULDs), such as xanthine oxidase inhibitors (XOIs), uricosuric agents, and uricase analogues, are the cornerstone of chronic gout management. Despite the availability of these treatments, physicians, patients, and healthcare systems have concerns about their limitations. The gout therapy market will expand over the 2022-2032 study period, fueled by an increasing diagnosed gout population and demand for new drugs that can effectively, safely, and conveniently control the disease. Several drugs are in clinical development, including uricase analogues, XOIs, URAT1 inhibitors, and inhibitors of the NOD-like receptor protein-3 (NLRP3) inflammasome.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.